Quantcast

RE2 Robotics and Clinical Platform top Pittsburgh's recent funding news

RE2 Robotics and Clinical Platform top Pittsburgh's recent funding news
Photo: RE2 Robotics/Facebook
By Hoodline - Published on June 12, 2019.

Pittsburgh-based robotics and software engineering company RE2 Robotics has secured $3 million in grant funding, according to company database Crunchbase, topping the city’s recent funding headlines. The cash infusion was announced May 20 and financed by the Office of Naval Research.

According to its Crunchbase profile, "RE2 Robotics, located in Pittsburgh, PA., is a Carnegie Mellon spin-off. We were founded in 2001 by Jorgen Pedersen on the principles of developing innovative robotic technologies that save lives and improve quality of life. Our team designs mobile manipulation technologies that enable robot users to remotely interact with the world — whether on the ground, in the air or underwater."

The 18-year-old company has raised three previous funding rounds, including a $1 million grant in 2017.

Over the past year, three Pittsburgh-based government and military companies have secured venture funding, totaling $3.1 million in new investment to the local industry.

In other local funding news, health diagnostics and video company Clinical Platform announced a $20,000 funding round on June 6, financed by Pittsburgh Life Sciences Greenhouse.

According to Crunchbase, "Clinical Platform creates short-form, video-based patient and caregiver information for people that have cancer and then connects them to clinical trials. The purpose of our business is to improve the outcomes of cancer patients by providing easily accessible and retainable information on the diagnosis of, treatments for, and living with any type of cancer. It is a fact that better educated patients have improved outcomes."

The company also raised a convertible note round in 2017.


This story was created automatically using local investment data, then reviewed by an editor. Click here for more about what we're doing. Got thoughts? Go here to share your feedback.